PHARMACOECONOMICS OF ORAL PARICALCITOL THERAPY IN PATIENTS WITH A CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYROIDISM
https://doi.org/10.24884/1561-6274-2019-23-1-67-72
Abstract
Selective vitamin D receptors agonist paricalcitol can increase probability of proteinuria reduction at patients with the chronic kidney disease (CKD) and secondary hyperparathyroid-ism. THE AIM of this study was to determine the cost effectiveness of oral paricalcitol in patients with a CKD and secondary hyperparathyroidism and to carry out the budget impact analysis to understand the potential financial effect of introducing this drug in a health plan. MATERIALS AND METHODS. Assessment was carried out from a health care payer per-spective with use of the 5-year temporary horizon. Markov modeling on the basis of results of double blind trials at whom the efficacy of a paricalcitol at patients with hyperparathyroidism was estimated is carried out. The analysis is carried out taking into account tariffs of compulsory health insurances across St. Petersburg for 2018. Cost of paricalcitol corresponded to the price of registration including VAT for 2018 and 10% of a trade extra charge (5061.27 rub for 28 caps. on 1 mcg). During cost-effectiveness assessment clinical and economic outcomes were discounted at 3,5% a year. The budget impact analysis was carried out without discount-ing. RESULTS. Purpose of an oral paricalcitol to patients with CKD stage 3-4 and secondary hyperparathyroidism allows to increase time before transition to dialysis and life expectancy on average for 0,049-0,134 and for 0,033-0,144 year, respectively (when calculating without dis-counting). The cost effectiveness of an oral paricalcitol is higher at early stages of a nephropathy – 1,377 million rubles / year without dialysis gained, 1,408 million rubles / life year gained and 1,647 million rubles / QALY. At the same time paricalcitol therapy of patients with early stages of a nephropathy demands increase of cumulative expenses in 5 years by 2,24 times. CONCLUSIONS. Oral paricalcitol therapy in patients with a CKD and secondary hyperparathyroidism, according to results of modeling, allows to postpone transition of patients to dial-ysis and, taking into account the made assumptions, can be considered in patients with early stages of a nephropathy as economically acceptable intervention.
About the Author
A. V. Rudakova
Department of management and economy of pharmacy, Saint Petersburg State Chemical Pharmaceutical University
Russian Federation
Russian Federation
Alla V. Rudakova, PhD, DPharmSci
197022, Saint Petersburg, Professora Popova Str., 14 A
Phone: +7(921)908-73-49
References
1. Agarwal R, Acharya M, Tian J et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney International 2005; 68: 2823–2828. Doi: 10.1111/j.1523-1755.2005.00755.x
2. Alborzi P, Patel N, Peterson C et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease. A randomized double-blind pilot trial. Hypertension 2008; 52: 249–255. Doi: 10.1161/HYPERTENSIONAHA.108.113159
3. de Zeeuw D, Agarwal R, Amdahl M et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376 (9752): 1543–1551. Doi: 10.1016/S0140-6736(10)61032-X
4. Hu X, Shang J, Yuan W et al. Effects of paricalcitol on cardiovascular outcomes and renal function in patients with chronic kidney disease: A meta-analysis. Herz 2018;43(6):518–528. Doi: 10.1007/s00059-017-4605-y
5. Lundwall K, Jacobson SH, Jörneskog G, Spaak J. Treating endothelial dysfunction with vitamin D in chronic kidney disease: a meta-analysis. BMC Nephrology 2018;19:247 Doi: 10.1186/s12882-018-1042-y
6. Zoccali C, Curatola G, Panuccio V et al. Paricalcitol and endothelial function in chronic kidney disease trial. Hypertension 2014; 64(5):1005–1011. Doi: 10.1161/HYPERTENSIONAHA.114.03748
7. Marx SE, Frye C, Khan S et al. Dialysis health outcomes associated with pre-dialysis use of paricalcitol for secondary hyperparathyroidism (SHPT). International Society for Pharmacoeconomics & Outcomes Research Atlanta, Georgia May 17–19, 2010
8. Hadjiyannakos D, Filiopoulos V, Trompouki S et al. Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3–4: a preliminary study. Clin Kidney J 2013; 6: 164–168. Doi: 10.1093/ckj/sfs188
9. Guideline for the Evaluation and Management of KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International 2013; 3(1). Doi:10.1038/kisup.2012.73
10. Рекомендации Ассоциации нефрологов и Научного общества нефрологов России «Минеральные и костные нарушения при хронической болезни почек (МКН-ХБП) (2015 г.) www.non.ru [Rekomendacii Associacii nefrologov i Nauchnogo obshchestva nefrologov Rossii «Mineral'nye i kostnye narusheniya pri hronicheskoj bolezni pochek (MKN–HBP) (2015 g.) www.non.ru]
11. Palmer AJ, Annemans L, Roze S et al. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care 2004; 27 (8): 1897–903. Doi: 10.2337/diacare.27.8.1897
12. Рудакова АВ. Фармакоэкономические аспекты терапии алискиреном артериальной гипертензии у пациентов с сахарным диабетом 2 типа и нефропатией. Клиническая фармакология и терапия 2009; 4: 48–50 [Rudakova AV. Farmakoehkonomicheskie aspekty terapii aliskirenom arterial'noj gipertenzii u pacientov s saharnym diabetom 2 tipa i nefropatiej. Klinicheskaya farmakologiya i terapiya. 2009; 4: 48–50]
13. Obermüller N, Rosenkranz A, Müller H-W et al. Long-Term Therapy Outcomes When Treating Chronic Kidney Disease Patients with Paricalcitol in German and Austrian Clinical Practice (TOP Study). Int J Mol Sci 2017; 18: 2057. Doi: 10.3390/ijms18102057
14. Приложения к Генеральному тарифному соглашению по тарифам на медицинскую помощь (медицинские услуги) и условиям оплаты медицинской помощи, оказываемой в рамках действующей Территориальной программы обязательного медицинского страхования граждан Российской Федерации в Санкт-Петербурге на 2018 г. (www.spboms.ru) [Prilozheniya k General'nomu tarifnomu soglasheniyu po tarifam na medicinskuyu pomoshch' (medicinskie uslugi) i usloviyam oplaty medicinskoj pomoshchi, okazyvaemoj v ramkah dejstvuyushchej Territorial'noj programmy obyazatel'nogo medicinskogo strahovaniya grazh dan Rossijskoj Federacii v Sankt-Peterburge na 2018 g. (www. spboms.ru)]
15. Kelley K, Aricak O, Light R, Agarwal R. Proteinuria is a determinant of quality of life in diabetic nephropathy: modeling lagged effects with path analysis. Am J Nephrol 2007; 27 (5): 488–494. Doi: 10.1159/000106672
16. Brown GC, Brown MM, Sharma S et al. Quality of life associated with diabetes mellitus in an adult population. J Diabetes Complications 2000; 14 (1): 18–24. Doi: 10.1016/S1056-8727(00)00061-1
17. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000; 38 (6): 583–637. Doi: 10.1097/00005650-200006000-00004
18. Coyne D, Goldberg S, Faber M et al. A Randomized Multicenter Trial of Paricalcitol versus Calcitriol for Secondary Hyperparathyroidism in Stages 3–4 CKD. Clin J Am Soc Nephrol 2014; 9: 1620–1626. Doi: 10.2215/CJN.10661013
19. Palmer SC, McGregor DO, Macaskill P et al. Meta-analysis: Vitamin D compounds in chronic kidney disease. Ann Intern Med 2007; 147: 840–853. Doi:10.2215/CJN.04520908
20. Cai P, Tang X, Qin W et al. Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. International Urology and Nephrology 2016; 48(4):571–584. Doi:10.1007/s11255-015-1195-6
Review
For citations:
Rudakova A.V. PHARMACOECONOMICS OF ORAL PARICALCITOL THERAPY IN PATIENTS WITH A CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYROIDISM. Nephrology (Saint-Petersburg). 2019;23(1):67-72. (In Russ.) https://doi.org/10.24884/1561-6274-2019-23-1-67-72
Views:
606
Email this article 